中华皮肤科杂志 ›› 2007, Vol. 40 ›› Issue (12): 717-719.

• 论著 •    下一篇

溴夫定治疗带状疱疹的疗效和安全性评价

王爱平1, 漆军2, 王宏伟3, 赵庆利4, 朱威5, 余进1, 赵华2, 李红春3, 刘雯4, 赵琛5, 汪科1, 李恒进2, 王宝玺3, 赵广4, 连石5, 朱学骏1   

  1. 1. 北京大学第一医院皮肤性病科 100034;
    2. 解放军总医院皮肤科;
    3. 中国医学科学院北京协和医院皮肤性病科;
    4. 解放军空军总医院皮肤科;
    5. 首都医科大学宣武医院皮肤性病科
  • 收稿日期:2007-01-15 出版日期:2007-12-15 发布日期:2007-12-15
  • 通讯作者: 朱学骏,email:zhuj@public.bta.net.cn E-mail:zhuj@public.bta.net.cn

Evaluation of efficacy and safety of brivudine once daily versus 4 times daily in the treatment of herpes zoster

WANG Ai-ping1, QI Jun2, WANG Hong-wei3, ZHAO Qing-li4, ZHU Wei5, YU Jin1, ZHAO Hua2, LI Hong-chun3, LIU Wen4, ZHAO Chen5, WANG Ke1, LI Heng-jin2, WANG Bao-xi3, ZHAO Guang4, LIAN Shi5, ZHU Xue-jun1   

  1. Department of Dermatology and Venereology, Peking University First Hospital, Beijing 100034, China
  • Received:2007-01-15 Online:2007-12-15 Published:2007-12-15

PDF (PC)

274

赞

摘要： 目的 评价溴夫定125mg每天1次和每天4次治疗带状疱疹的疗效和安全性.方法 多中心、随机、双盲、平行对照临床试验.226例带状疱疹患者分别接受溴夫定125mg每天1次(112例)或每天4次(114例)治疗,疗程7d,再随访3周.结果 新水疱停止出现时间,单次剂量组平均为3.88d,4次剂量组为3.79d,两组比较,差异无统计学意义.水疱完全消退时间、开始结痂时间、全部结痂时间、开始脱痂时间、全部脱痂时间、疼痛开始减轻时间和疼痛完全消失时间两组比较,差异均无统计学意义.单次剂量组有34.5%、4次剂量组有30.4%的患者皮损痊愈后仍存在疱疹相关疼痛.药物相关不良反应发生率分别为5.4%和9.6%.结论 溴夫定125mg每天1次和每天4次治疗带状疱疹同样有效,但单次剂量组更方便、安全.

关键词: 溴夫定, 疱疹, 带状, 随机对照试验

Abstract: Objective To assess efficacy and safety of oral brivudine 125 mg once daily versus 4 times daily in the treatment of herpes zoster.Methods A five-centre,randomized,double-blind,parallelcontrolled study was performed on 226 patients with herpes zoster.Oral brivudine 125 mg was given once daily to 112 patients,and four times daily to 114 patients,both for 7 days.All patients were followed up for 3 weeks after the end of treatment.Results The time to the last formation of new vesicles was 3.88 days for the once daily group,and 3.79 days for the 4 times daily group,without significant differences between the two groups.There was also no significant difference between the two groups with respect to the time to total resolution of vesicles,time to first crusts,time to full crusting,time to first loss of crusts,time to full loss of crusts,time to first relief of pain,and time to complete relief of pain.Postherpetic neuralgia occurred in 34.5% of patients in the once daily group,and 30.4% of patients in the 4 times daily group.The incidence of treatment-related adverse events was 5.4% and 9.6%,in the once daily group and 4 times daily group, respectively.Conclusions Brivudine 125 mg once daily is equally effective,more convenient and safe in comparison with brivudine 125 mg 4 times daily for the treatment of herpes zoster.

Key words: Brivudine, Herpes zoster, Randomized controlled trials